European Journal of Clinical Pharmacology

, Volume 31, Issue 1, pp 23–26 | Cite as

5-Aminosalicylic acid in patients with an ileo-rectal anastomosis

A comparison of the fate of sulfasalazine and Pentasa
  • S. Bondesen
  • U. Tage-Jensen
  • O. Jacobsen
  • S. H. Hansen
  • S. N. Rasmussen
  • E. F. Hvidberg


The pharmacokinetics of 5-aminosalicylic acid (5-ASA) from sulphasalazine (SASP) and the slow-release 5-ASA preparation Pentasa was investigated in a cross-over study in 9 otherwise healthy patients with an ileo-rectal anastomosis. The 24-hour recoveries of the drugs were 90.5% and 84.7%, respectively. The median release of 5-ASA from SASP was 50% and from Pentasa 75%. Equal amounts of 5-ASA (18.0% vs 17.9%) were found in the faeces, and a significantly larger amount (4.4% vs 28.9%) of the metaboliteN-acetyl-5-aminosalicylic acid (ac-5-ASA) was found in faeces following Pentasa. A larger amount of 5-ASA was absorbed and subsequently excreted in the urine, mainly as the metabolite (2.5% vs 20.5%) from Pentasa. This confirms previous results in ileostomized patients treated with Pentasa. The present findings also demonstrate that bacterial azo-reduction of SASP in patients with ileorectal anastomosis may be an adequate way to deliver 5-ASA in this type of patient. Both treatments may be used in these patients during a flare up of ulcerative colitis, but randomized studies are needed.

Key words

sulphasalazine Pentasa slow release preparation 5-aminosalicylic acid ileo-rectal anastomosis ulcerative colitis pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lennard-Jones JE, Powell-Tuck J (1979) Drug treatment of inflammatory disease. Clin Gastroenterol 8: 187–217Google Scholar
  2. 2.
    Summers WR, Switz DM, Sessions JT Jr et al. (1979) National cooperative Crohn's disease study: Results of drug treatment. Gastroenterology 77: 847–869Google Scholar
  3. 3.
    Peppercorn MA, Goldman P (1973) Distribution studies of salicylazosulphapyridine and its metabolites. Gastroenterology 64: 240–245Google Scholar
  4. 4.
    Khan AKA, Piris J, Truelove SC (1977) An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2: 892–895Google Scholar
  5. 5.
    van Hees PAM, Tuinte JHM, van Rossum JM, van Tongeren JHM (1979) Influence of intestinal transittime on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut 20: 300–304Google Scholar
  6. 6.
    Das KM, Chowdhury JR, Zapp B, Fara JW (1979) Small bowel absorption of sulphasalazine and its hepatic metabolism in human beings, cats and rats. Gastroenterology 77: 280–284Google Scholar
  7. 7.
    Hansen SH (1981) Assay of 5-aminosalicylate and its acetylated metabolite in biological fluids by high performance liquid chromatography on dynamically modified silica. J Chromatogr 226: 504–509Google Scholar
  8. 8.
    Bondesen S, Nielsen OH, Schou JB, Jensen PH, Lassen LB, Hansen SH, Rasmussen SN, Binder V, Krasilnikoff PA, Danø P, Hvidberg EF (1986) Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulphasalazine prophylaxis in ulcerative colitis. Scand J Gastroenterol (in press)Google Scholar
  9. 9.
    Das KM, Eastwood MA, McManus JPA, Sircus W (1974) The role of the colon in the metabolism of salicylazosulphapyridine. Scand J Gastroenterol 9: 137–141Google Scholar
  10. 10.
    van Hees PAM (1979) Clinical and pharmacological aspects of sulfasalazine (Thesis). Gist-Brocades NV, Delft 1979Google Scholar
  11. 11.
    Peppercorn MA, Goldman P (1972) The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 181: 555–562Google Scholar
  12. 12.
    Chan RP, Pope DJ, Gilbert AP, Sacra PJ, Baron JH, Lennard-Jones JE (1983) Studies of two novel sulfasalazine analogs, Ipsalazide and Balsalazide. Dig Dis Sci 28: 609–615Google Scholar
  13. 13.
    Willoughby CP, Aronson JK, Agback H, Bodin NO, Truelove SC (1982) Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut 23: 1081–1087Google Scholar
  14. 14.
    van Hees PAM, van Lier HJJ, van Eltern PH, Driessen WMM, van Hogezand RA, Ten Velde GPM, Bakker JH, van Tongeren JHM (1981) Effect of sulphasalazine in patients with active Crohn's disease: A controlled double-blind study. Gut 22: 404–409Google Scholar
  15. 15.
    Palmer KR, Goepel JR, Holdsworth CD (1981) Sulphasalazine retention enemas in ulcerative colitis: A double-blind trial. Br Med J 282: 1571–1573Google Scholar
  16. 16.
    Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, Flachs H (1982) 5-aminosalicylic acid in a slow-release preparation: Bioavailability, plasma level and excretion in humans. Gastroenterology 83: 1062–1070Google Scholar
  17. 17.
    Allgayer H, Eisenburg J, Paumgartner G (1984) Soybean lipoxygenase inhibition — studies with the sulphasalazine metabolitesN-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridin. Eur J Clin Pharmacol 26: 449–451Google Scholar
  18. 18.
    Willoughby CP, Piris J, Truelove SC (1980) The effect of topicalN-acetyl-5-aminosalicylic acid in ulcerative colitis. Scand J Gastroenterol 15: 715–719Google Scholar
  19. 19.
    Binder V, Halskov S, Hvidberg EF, Kristensen E, Riis P, Tougaard L, Willumsen L (1981) A controlled study of 5-acetyl-aminosalicylic acid as enemas in ulcerative colitis. Scand J Gastroenterol 16: 1122Google Scholar
  20. 20.
    Fischer C, Maier K, Stumpf E, von Gaisburg U, Klotz U (1983) Disposition of 5-aminosalicylic acid, the active metabolite of sulfasalazine, in man. Eur J Clin Pharmacol 25: 511–515Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • S. Bondesen
    • 1
  • U. Tage-Jensen
    • 2
  • O. Jacobsen
    • 3
  • S. H. Hansen
    • 4
  • S. N. Rasmussen
    • 2
  • E. F. Hvidberg
    • 5
  1. 1.Department of MedicineCommunity HospitalElsinoreDenmark
  2. 2.Department of Medical Gastroenterology FGlostrup HospitalCopenhagenDenmark
  3. 3.Department of Medicine P, Division of Gastroenterology, RigshospitaletUniversity of CopenhagenCopenhagenDenmark
  4. 4.Department of Organic ChemistryRoyal Danish School of PharmacyCopenhagenDenmark
  5. 5.Department of Clinical Pharmacology, RigshospitaletUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations